During the forecast period, the APAC hemodialysis and peritoneal dialysis market is expected to grow at a CAGR of 9.08% and be worth USD 25.02 billion by 2027 from USD 16.20 billion in 2022.
The growing incidence of acute kidney injury cases is the primary factor propelling the hemodialysis and peritoneal dialysis market in the Asia-Pacific region. In 2019, the Malaysian Society of Nephrology announced that due to an increase in acute kidney injury and renal replacement therapy, they had provided information and awareness about these diseases and utilization of advanced treatment to cure the diseases. Peritoneal Dialysis is used for most AKI patients because of its lower cost and minimal infrastructural requirements.
Risks and side effects associated with transplantation procedures are anticipated to promote market growth. Respiratory viruses, parvovirus B19 infection, and Gastrointestinal viruses are the most common acquired infections in transplantation recipients. In addition, the issues after kidney transplantation include blood clots, flues, viral infections, blood clots, blocked ureter, and Urine leakage. Knowing about all these issues, a certain number of people are adopting dialysis treatment for purifying blood or removing waste from the blood, increasing the demand for this Dialysis.
Increasing chronic diseases such as diabetes, obesity, and hypertension also result in causing various diseases in the body. These diseases result in causing eye problems, blood vessel problems, liver problems, and kidney problems. For example, increasing diabetes cases in India are due to rising rates of overweight/obesity and unhealthy lifestyles. In India, nearly 78 million people had diabetes in 2019, which is expected to increase by 136 million by 2045.
Due to the decreasing number of organ donations in Asia-Pacific countries such as India, the need for hemodialysis and peritoneal Dialysis is anticipated to grow. A smaller number of hospitals in India perform organ transplantation with high infrastructure. According to recent statistics, organ donation in India organ transplantation in India is meager due to the unavailability of organs. Nearly 2.2 lakh people are waiting for a kidney transplant. According to the World Health Organization report, in 2019, 500,000 people are waiting for an organ transplant in India. These people undergo Dialysis to increase their lifespan, which boosts the market forward in this Asia Pacific region.
On the other hand, growing complications in dialysis treatment, lack of reimbursement policies, the lengthy approval process for Dialysis, and product recalls are the factors restraining the market growth.
This research report on the APAC hemodialysis and peritoneal dialysis market has been segmented and sub-segmented into the following categories.
By Type:
By Product:
By End-User:
By Country:
The APAC region is anticipated to grow the fastest among all the regions in the global market. The Indian market is estimated to showcase rapid growth during the forecast period in this region. Most adults in India suffer from AKI problems that sometimes lead to death. Due to increasing cases of kidney failure in India, most people are adopting peritoneal dialysis (PD) or hemodialysis (HD) treatment. Chronic kidney disease (CKD) is India's global public health problem. Nearly 18 percent of Indians suffer from these kidney diseases. The number of people suffering from end-stage renal disease in India is increasing yearly. There are almost 5,00,000 ESRD patients in India. These patients prefer Hospital-based hemodialysis (HD) or home-based Continuous Ambulatory Peritoneal Dialysis treatment. Peritoneal Dialysis is a safe, efficient, cost-effective, and patient-friendly treatment in India.
On the other hand, the Chinese market is expected to progress at a healthy CAGR. Due to the increase in chronic kidney disease (CKD) in China every year, the Chinese government has introduced an insurance system for the patient’s families. It provides the best treatment for diseased patients. In China, peritoneal dialysis (PD) utilization has increased faster than hemodialysis. The Chinese government is more focused on improving patient care, increasing the quality of care for Dialysis diseased patients, and increasing advanced products in peritoneal dialysis, which boosts the market forward.
The Japanese market is also expected to grow at a promising CAGR during the forecast period. According to the Japanese Society for Dialysis Therapy report, 335,575 patients are receiving dialysis treatment in Japan as of 2018. In addition, most people prefer home dialysis treatment in Japan. This factor boosts the market growth forward in Japan.
KEY MARKET PLAYERS:
Companies playing a significant role in the APAC hemodialysis and peritoneal dialysis market profiled in this report are Straumann Holding AG, Geistlich Pharma AG, Zimmer Biomet Holdings, Inc., Danaher Corporation, Dentsply Sirona, Inc., 3M Company, Royal DSM, Carpenter Technology Corporation, Kuraray Co., Ltd., and Henry Schein, Inc.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region